Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology.
Identifieur interne : 001577 ( Main/Exploration ); précédent : 001576; suivant : 001578Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology.
Auteurs : Yoshikazu Honda-Okubo [Australie] ; Dale Barnard [États-Unis] ; Chun Hao Ong [Australie] ; Bi-Hung Peng [États-Unis] ; Chien-Te Kent Tseng [États-Unis] ; Nikolai Petrovsky [Australie]Source :
- Journal of virology [ 1098-5514 ] ; 2015.
Descripteurs français
- KwdFr :
- Adjuvants immunologiques (administration et posologie), Animaux, Femelle, Glycoprotéine de spicule des coronavirus (administration et posologie), Glycoprotéine de spicule des coronavirus (génétique), Glycoprotéine de spicule des coronavirus (immunologie), Granulocytes éosinophiles (immunologie), Humains, Immunisation, Interféron gamma (immunologie), Interleukine-4 (immunologie), Inuline (administration et posologie), Inuline (analogues et dérivés), Lymphocytes auxiliaires Th1 (immunologie), Poumon (anatomopathologie), Poumon (immunologie), Souris, Souris de lignée BALB C, Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (anatomopathologie), Syndrome respiratoire aigu sévère (immunologie), Syndrome respiratoire aigu sévère (virologie), Vaccins antiviraux (administration et posologie), Vaccins antiviraux (génétique), Vaccins antiviraux (immunologie), Virus du SRAS (génétique), Virus du SRAS (immunologie).
- MESH :
- administration et posologie : Adjuvants immunologiques, Glycoprotéine de spicule des coronavirus, Inuline, Vaccins antiviraux.
- analogues et dérivés : Inuline.
- anatomopathologie : Poumon, Syndrome respiratoire aigu sévère.
- génétique : Glycoprotéine de spicule des coronavirus, Vaccins antiviraux, Virus du SRAS.
- immunologie : Glycoprotéine de spicule des coronavirus, Granulocytes éosinophiles, Interféron gamma, Interleukine-4, Lymphocytes auxiliaires Th1, Poumon, Syndrome respiratoire aigu sévère, Vaccins antiviraux, Virus du SRAS.
- virologie : Syndrome respiratoire aigu sévère.
- Animaux, Femelle, Humains, Immunisation, Souris, Souris de lignée BALB C, Syndrome respiratoire aigu sévère.
English descriptors
- KwdEn :
- Adjuvants, Immunologic (administration & dosage), Animals, Eosinophils (immunology), Female, Humans, Immunization, Interferon-gamma (immunology), Interleukin-4 (immunology), Inulin (administration & dosage), Inulin (analogs & derivatives), Lung (immunology), Lung (pathology), Mice, Mice, Inbred BALB C, SARS Virus (genetics), SARS Virus (immunology), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (pathology), Severe Acute Respiratory Syndrome (prevention & control), Severe Acute Respiratory Syndrome (virology), Spike Glycoprotein, Coronavirus (administration & dosage), Spike Glycoprotein, Coronavirus (genetics), Spike Glycoprotein, Coronavirus (immunology), Th1 Cells (immunology), Viral Vaccines (administration & dosage), Viral Vaccines (genetics), Viral Vaccines (immunology).
- MESH :
- chemical , administration & dosage : Adjuvants, Immunologic, Inulin, Spike Glycoprotein, Coronavirus, Viral Vaccines.
- chemical , analogs & derivatives : Inulin.
- genetics : SARS Virus, Spike Glycoprotein, Coronavirus, Viral Vaccines.
- immunology : Eosinophils, Interferon-gamma, Interleukin-4, Lung, SARS Virus, Severe Acute Respiratory Syndrome, Spike Glycoprotein, Coronavirus, Th1 Cells, Viral Vaccines.
- pathology : Lung, Severe Acute Respiratory Syndrome.
- prevention & control : Severe Acute Respiratory Syndrome.
- virology : Severe Acute Respiratory Syndrome.
- Animals, Female, Humans, Immunization, Mice, Mice, Inbred BALB C.
Abstract
Although the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) epidemic was controlled by nonvaccine measures, coronaviruses remain a major threat to human health. The design of optimal coronavirus vaccines therefore remains a priority. Such vaccines present major challenges: coronavirus immunity often wanes rapidly, individuals needing to be protected include the elderly, and vaccines may exacerbate rather than prevent coronavirus lung immunopathology. To address these issues, we compared in a murine model a range of recombinant spike protein or inactivated whole-virus vaccine candidates alone or adjuvanted with either alum, CpG, or Advax, a new delta inulin-based polysaccharide adjuvant. While all vaccines protected against lethal infection, addition of adjuvant significantly increased serum neutralizing-antibody titers and reduced lung virus titers on day 3 postchallenge. Whereas unadjuvanted or alum-formulated vaccines were associated with significantly increased lung eosinophilic immunopathology on day 6 postchallenge, this was not seen in mice immunized with vaccines formulated with delta inulin adjuvant. Protection against eosinophilic immunopathology by vaccines containing delta inulin adjuvants correlated better with enhanced T-cell gamma interferon (IFN-γ) recall responses rather than reduced interleukin-4 (IL-4) responses, suggesting that immunopathology predominantly reflects an inadequate vaccine-induced Th1 response. This study highlights the critical importance for development of effective and safe coronavirus vaccines of selection of adjuvants based on the ability to induce durable IFN-γ responses.
DOI: 10.1128/JVI.02980-14
PubMed: 25520500
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001751
- to stream PubMed, to step Curation: 001751
- to stream PubMed, to step Checkpoint: 001349
- to stream Ncbi, to step Merge: 000F98
- to stream Ncbi, to step Curation: 000F98
- to stream Ncbi, to step Checkpoint: 000F98
- to stream Main, to step Merge: 001582
- to stream Main, to step Curation: 001577
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology.</title><author><name sortKey="Honda Okubo, Yoshikazu" sort="Honda Okubo, Yoshikazu" uniqKey="Honda Okubo Y" first="Yoshikazu" last="Honda-Okubo">Yoshikazu Honda-Okubo</name><affiliation wicri:level="1"><nlm:affiliation>Vaxine Pty Ltd., Adelaide, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Vaxine Pty Ltd., Adelaide</wicri:regionArea><wicri:noRegion>Adelaide</wicri:noRegion></affiliation></author><author><name sortKey="Barnard, Dale" sort="Barnard, Dale" uniqKey="Barnard D" first="Dale" last="Barnard">Dale Barnard</name><affiliation wicri:level="2"><nlm:affiliation>Institute for Antiviral Research, Utah State University, Logan, Utah, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Institute for Antiviral Research, Utah State University, Logan, Utah</wicri:regionArea><placeName><region type="state">Utah</region></placeName></affiliation></author><author><name sortKey="Ong, Chun Hao" sort="Ong, Chun Hao" uniqKey="Ong C" first="Chun Hao" last="Ong">Chun Hao Ong</name><affiliation wicri:level="1"><nlm:affiliation>Vaxine Pty Ltd., Adelaide, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Vaxine Pty Ltd., Adelaide</wicri:regionArea><wicri:noRegion>Adelaide</wicri:noRegion></affiliation></author><author><name sortKey="Peng, Bi Hung" sort="Peng, Bi Hung" uniqKey="Peng B" first="Bi-Hung" last="Peng">Bi-Hung Peng</name><affiliation wicri:level="2"><nlm:affiliation>University of Texas Medical Branch, Galveston, Texas, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Texas Medical Branch, Galveston, Texas</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Tseng, Chien Te Kent" sort="Tseng, Chien Te Kent" uniqKey="Tseng C" first="Chien-Te Kent" last="Tseng">Chien-Te Kent Tseng</name><affiliation wicri:level="2"><nlm:affiliation>University of Texas Medical Branch, Galveston, Texas, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Texas Medical Branch, Galveston, Texas</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Petrovsky, Nikolai" sort="Petrovsky, Nikolai" uniqKey="Petrovsky N" first="Nikolai" last="Petrovsky">Nikolai Petrovsky</name><affiliation wicri:level="1"><nlm:affiliation>Vaxine Pty Ltd., Adelaide, Australia Department of Diabetes and Endocrinology, Flinders University, Adelaide, Australia nikolai.petrovsky@flinders.edu.au.</nlm:affiliation><country wicri:rule="url">Australie</country><wicri:regionArea>Vaxine Pty Ltd., Adelaide, Australia Department of Diabetes and Endocrinology, Flinders University, Adelaide</wicri:regionArea><wicri:noRegion>Adelaide</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25520500</idno><idno type="pmid">25520500</idno><idno type="doi">10.1128/JVI.02980-14</idno><idno type="wicri:Area/PubMed/Corpus">001751</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001751</idno><idno type="wicri:Area/PubMed/Curation">001751</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001751</idno><idno type="wicri:Area/PubMed/Checkpoint">001349</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001349</idno><idno type="wicri:Area/Ncbi/Merge">000F98</idno><idno type="wicri:Area/Ncbi/Curation">000F98</idno><idno type="wicri:Area/Ncbi/Checkpoint">000F98</idno><idno type="wicri:Area/Main/Merge">001582</idno><idno type="wicri:Area/Main/Curation">001577</idno><idno type="wicri:Area/Main/Exploration">001577</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology.</title><author><name sortKey="Honda Okubo, Yoshikazu" sort="Honda Okubo, Yoshikazu" uniqKey="Honda Okubo Y" first="Yoshikazu" last="Honda-Okubo">Yoshikazu Honda-Okubo</name><affiliation wicri:level="1"><nlm:affiliation>Vaxine Pty Ltd., Adelaide, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Vaxine Pty Ltd., Adelaide</wicri:regionArea><wicri:noRegion>Adelaide</wicri:noRegion></affiliation></author><author><name sortKey="Barnard, Dale" sort="Barnard, Dale" uniqKey="Barnard D" first="Dale" last="Barnard">Dale Barnard</name><affiliation wicri:level="2"><nlm:affiliation>Institute for Antiviral Research, Utah State University, Logan, Utah, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Institute for Antiviral Research, Utah State University, Logan, Utah</wicri:regionArea><placeName><region type="state">Utah</region></placeName></affiliation></author><author><name sortKey="Ong, Chun Hao" sort="Ong, Chun Hao" uniqKey="Ong C" first="Chun Hao" last="Ong">Chun Hao Ong</name><affiliation wicri:level="1"><nlm:affiliation>Vaxine Pty Ltd., Adelaide, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Vaxine Pty Ltd., Adelaide</wicri:regionArea><wicri:noRegion>Adelaide</wicri:noRegion></affiliation></author><author><name sortKey="Peng, Bi Hung" sort="Peng, Bi Hung" uniqKey="Peng B" first="Bi-Hung" last="Peng">Bi-Hung Peng</name><affiliation wicri:level="2"><nlm:affiliation>University of Texas Medical Branch, Galveston, Texas, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Texas Medical Branch, Galveston, Texas</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Tseng, Chien Te Kent" sort="Tseng, Chien Te Kent" uniqKey="Tseng C" first="Chien-Te Kent" last="Tseng">Chien-Te Kent Tseng</name><affiliation wicri:level="2"><nlm:affiliation>University of Texas Medical Branch, Galveston, Texas, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Texas Medical Branch, Galveston, Texas</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Petrovsky, Nikolai" sort="Petrovsky, Nikolai" uniqKey="Petrovsky N" first="Nikolai" last="Petrovsky">Nikolai Petrovsky</name><affiliation wicri:level="1"><nlm:affiliation>Vaxine Pty Ltd., Adelaide, Australia Department of Diabetes and Endocrinology, Flinders University, Adelaide, Australia nikolai.petrovsky@flinders.edu.au.</nlm:affiliation><country wicri:rule="url">Australie</country><wicri:regionArea>Vaxine Pty Ltd., Adelaide, Australia Department of Diabetes and Endocrinology, Flinders University, Adelaide</wicri:regionArea><wicri:noRegion>Adelaide</wicri:noRegion></affiliation></author></analytic><series><title level="j">Journal of virology</title><idno type="eISSN">1098-5514</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (administration & dosage)</term><term>Animals</term><term>Eosinophils (immunology)</term><term>Female</term><term>Humans</term><term>Immunization</term><term>Interferon-gamma (immunology)</term><term>Interleukin-4 (immunology)</term><term>Inulin (administration & dosage)</term><term>Inulin (analogs & derivatives)</term><term>Lung (immunology)</term><term>Lung (pathology)</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>SARS Virus (genetics)</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (pathology)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Severe Acute Respiratory Syndrome (virology)</term><term>Spike Glycoprotein, Coronavirus (administration & dosage)</term><term>Spike Glycoprotein, Coronavirus (genetics)</term><term>Spike Glycoprotein, Coronavirus (immunology)</term><term>Th1 Cells (immunology)</term><term>Viral Vaccines (administration & dosage)</term><term>Viral Vaccines (genetics)</term><term>Viral Vaccines (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques (administration et posologie)</term><term>Animaux</term><term>Femelle</term><term>Glycoprotéine de spicule des coronavirus (administration et posologie)</term><term>Glycoprotéine de spicule des coronavirus (génétique)</term><term>Glycoprotéine de spicule des coronavirus (immunologie)</term><term>Granulocytes éosinophiles (immunologie)</term><term>Humains</term><term>Immunisation</term><term>Interféron gamma (immunologie)</term><term>Interleukine-4 (immunologie)</term><term>Inuline (administration et posologie)</term><term>Inuline (analogues et dérivés)</term><term>Lymphocytes auxiliaires Th1 (immunologie)</term><term>Poumon (anatomopathologie)</term><term>Poumon (immunologie)</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Syndrome respiratoire aigu sévère ()</term><term>Syndrome respiratoire aigu sévère (anatomopathologie)</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Syndrome respiratoire aigu sévère (virologie)</term><term>Vaccins antiviraux (administration et posologie)</term><term>Vaccins antiviraux (génétique)</term><term>Vaccins antiviraux (immunologie)</term><term>Virus du SRAS (génétique)</term><term>Virus du SRAS (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adjuvants, Immunologic</term><term>Inulin</term><term>Spike Glycoprotein, Coronavirus</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Inulin</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Adjuvants immunologiques</term><term>Glycoprotéine de spicule des coronavirus</term><term>Inuline</term><term>Vaccins antiviraux</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Inuline</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Poumon</term><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>SARS Virus</term><term>Spike Glycoprotein, Coronavirus</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Glycoprotéine de spicule des coronavirus</term><term>Vaccins antiviraux</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Glycoprotéine de spicule des coronavirus</term><term>Granulocytes éosinophiles</term><term>Interféron gamma</term><term>Interleukine-4</term><term>Lymphocytes auxiliaires Th1</term><term>Poumon</term><term>Syndrome respiratoire aigu sévère</term><term>Vaccins antiviraux</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Eosinophils</term><term>Interferon-gamma</term><term>Interleukin-4</term><term>Lung</term><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term><term>Spike Glycoprotein, Coronavirus</term><term>Th1 Cells</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Lung</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Female</term><term>Humans</term><term>Immunization</term><term>Mice</term><term>Mice, Inbred BALB C</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Femelle</term><term>Humains</term><term>Immunisation</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Syndrome respiratoire aigu sévère</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Although the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) epidemic was controlled by nonvaccine measures, coronaviruses remain a major threat to human health. The design of optimal coronavirus vaccines therefore remains a priority. Such vaccines present major challenges: coronavirus immunity often wanes rapidly, individuals needing to be protected include the elderly, and vaccines may exacerbate rather than prevent coronavirus lung immunopathology. To address these issues, we compared in a murine model a range of recombinant spike protein or inactivated whole-virus vaccine candidates alone or adjuvanted with either alum, CpG, or Advax, a new delta inulin-based polysaccharide adjuvant. While all vaccines protected against lethal infection, addition of adjuvant significantly increased serum neutralizing-antibody titers and reduced lung virus titers on day 3 postchallenge. Whereas unadjuvanted or alum-formulated vaccines were associated with significantly increased lung eosinophilic immunopathology on day 6 postchallenge, this was not seen in mice immunized with vaccines formulated with delta inulin adjuvant. Protection against eosinophilic immunopathology by vaccines containing delta inulin adjuvants correlated better with enhanced T-cell gamma interferon (IFN-γ) recall responses rather than reduced interleukin-4 (IL-4) responses, suggesting that immunopathology predominantly reflects an inadequate vaccine-induced Th1 response. This study highlights the critical importance for development of effective and safe coronavirus vaccines of selection of adjuvants based on the ability to induce durable IFN-γ responses.</div></front></TEI><affiliations><list><country><li>Australie</li><li>États-Unis</li></country><region><li>Texas</li><li>Utah</li></region></list><tree><country name="Australie"><noRegion><name sortKey="Honda Okubo, Yoshikazu" sort="Honda Okubo, Yoshikazu" uniqKey="Honda Okubo Y" first="Yoshikazu" last="Honda-Okubo">Yoshikazu Honda-Okubo</name></noRegion><name sortKey="Ong, Chun Hao" sort="Ong, Chun Hao" uniqKey="Ong C" first="Chun Hao" last="Ong">Chun Hao Ong</name><name sortKey="Petrovsky, Nikolai" sort="Petrovsky, Nikolai" uniqKey="Petrovsky N" first="Nikolai" last="Petrovsky">Nikolai Petrovsky</name></country><country name="États-Unis"><region name="Utah"><name sortKey="Barnard, Dale" sort="Barnard, Dale" uniqKey="Barnard D" first="Dale" last="Barnard">Dale Barnard</name></region><name sortKey="Peng, Bi Hung" sort="Peng, Bi Hung" uniqKey="Peng B" first="Bi-Hung" last="Peng">Bi-Hung Peng</name><name sortKey="Tseng, Chien Te Kent" sort="Tseng, Chien Te Kent" uniqKey="Tseng C" first="Chien-Te Kent" last="Tseng">Chien-Te Kent Tseng</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001577 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001577 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:25520500
|texte= Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25520500" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |